JP2006508912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508912A5 JP2006508912A5 JP2004530254A JP2004530254A JP2006508912A5 JP 2006508912 A5 JP2006508912 A5 JP 2006508912A5 JP 2004530254 A JP2004530254 A JP 2004530254A JP 2004530254 A JP2004530254 A JP 2004530254A JP 2006508912 A5 JP2006508912 A5 JP 2006508912A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- mol
- amphiphile
- optionally
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 claims 24
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 239000003381 stabilizer Substances 0.000 claims 7
- 239000008346 aqueous phase Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- KLHSDMQFUVANEB-MELZOAELSA-L hexadecyl-[(2r,3r)-4-[hexadecyl(dimethyl)azaniumyl]-2,3-dimethoxybutyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C[C@@H](OC)[C@H](OC)C[N+](C)(C)CCCCCCCCCCCCCCCC KLHSDMQFUVANEB-MELZOAELSA-L 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 150000002632 lipids Chemical group 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 3
- -1 scroll Natural products 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 230000008020 evaporation Effects 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000647 trehalose group Chemical group 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 240000007019 Oxalis corniculata Species 0.000 claims 1
- 235000016499 Oxalis corniculata Nutrition 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 150000003432 sterols Chemical group 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02018907A EP1393719A1 (en) | 2002-08-23 | 2002-08-23 | Camptothecin-carboxylate formulations |
| PCT/EP2003/006760 WO2004002454A1 (en) | 2002-06-26 | 2003-06-26 | Camptothecin-carboxylate formulations |
| PCT/EP2003/009398 WO2004017943A2 (en) | 2002-08-23 | 2003-08-25 | Non-vesicular cationic lipid formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508912A JP2006508912A (ja) | 2006-03-16 |
| JP2006508912A5 true JP2006508912A5 (cg-RX-API-DMAC7.html) | 2006-10-05 |
Family
ID=31947818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004530254A Pending JP2006508912A (ja) | 2002-08-23 | 2003-08-25 | 非小胞性カチオン脂質調製物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050232984A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1530456A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006508912A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003270102B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2495913A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004017943A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| KR101173510B1 (ko) | 2002-08-23 | 2012-08-21 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도 |
| JP2010505883A (ja) | 2006-10-12 | 2010-02-25 | ザ ユニバーシティー オブ クイーンズランド | 免疫応答を調節するための組成物および方法 |
| MX2011003207A (es) * | 2008-09-27 | 2011-11-04 | Jina Pharmaceuticals Inc | Preparaciones farmaceuticas a base de lipidos para la aplicacion oral y topica; sus composiciones, metodos y usos. |
| US10058634B2 (en) | 2009-04-28 | 2018-08-28 | Surmodics, Inc. | Devices and methods for delivery of bioactive agents |
| CA2816529A1 (en) | 2010-11-01 | 2012-05-10 | University Of Technology, Sydney | Immune-modulating agents and uses therefor |
| US20140127288A1 (en) * | 2011-05-17 | 2014-05-08 | Mitsubishi Gas Chemical Company, Inc. | Liposome containing pyrroloquinoline quinone and sugar |
| US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
| US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
| CA2890205C (en) * | 2012-11-05 | 2020-12-22 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
| US11246963B2 (en) | 2012-11-05 | 2022-02-15 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
| US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
| WO2015179918A1 (en) | 2014-05-27 | 2015-12-03 | The University Of Queensland | Modulation of cellular stress |
| HUE054894T2 (hu) | 2014-11-05 | 2021-10-28 | Selecta Biosciences Inc | Rapamicint stabil, túltelített állapotban tartalmazó szintetikus nanohordozókkal kapcsolatos módszerek és készítmények |
| EP3283045B1 (en) * | 2015-04-13 | 2021-02-17 | Fountain Technologies International, LLC | One-step method for production of ultra-small lipid structures |
| US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
| US12226552B2 (en) | 2019-09-30 | 2025-02-18 | Surmodics, Inc. | Active agent depots formed in situ |
| US20210308058A1 (en) | 2020-03-11 | 2021-10-07 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3585967D1 (de) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | Liposombildende zusammensetzung. |
| US4830858A (en) * | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| DE4430593C2 (de) * | 1994-08-20 | 1999-01-14 | Max Delbrueck Centrum | Verfahren zur Herstellung von Liposomal verkapseltem Taxol |
| US5834012A (en) * | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
| US5753262A (en) * | 1995-06-07 | 1998-05-19 | Aronex Pharmaceuticals, Inc. | Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| EP1138313A1 (de) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Pro-liposomen |
| EP1138310A1 (de) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Pro-liposomen |
| US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| AU2001275423B2 (en) * | 2000-06-09 | 2007-01-11 | Regulon, Inc. | Encapsulation of polynucleotides and drugs into targeted liposomes |
| JP4536235B2 (ja) * | 2000-09-18 | 2010-09-01 | 本田技研工業株式会社 | ハイドロゲル |
-
2003
- 2003-08-25 US US10/525,384 patent/US20050232984A1/en not_active Abandoned
- 2003-08-25 EP EP03750438A patent/EP1530456A2/en not_active Withdrawn
- 2003-08-25 CA CA002495913A patent/CA2495913A1/en not_active Abandoned
- 2003-08-25 AU AU2003270102A patent/AU2003270102B2/en not_active Ceased
- 2003-08-25 JP JP2004530254A patent/JP2006508912A/ja active Pending
- 2003-08-25 WO PCT/EP2003/009398 patent/WO2004017943A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508912A5 (cg-RX-API-DMAC7.html) | ||
| JP7066632B2 (ja) | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 | |
| Crommelin et al. | The role of liposomes in clinical nanomedicine development. What now? Now what? | |
| Jadhav et al. | Novel vesicular system: an overview | |
| KR101780915B1 (ko) | 이리노테칸 또는 그의 하이드로클로라이드의 리포좀 및 그의 제조 방법 | |
| EP2108362B1 (en) | A cationic liposomal preparation comprising a taxane | |
| EP2608785B1 (en) | Lipomacrocycles and uses thereof | |
| JP2006517594A (ja) | リポソーム製剤の製造方法 | |
| WO2003057128A3 (en) | Lipid particles and suspensions and uses thereof | |
| US20190328665A1 (en) | Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof | |
| US20050232984A1 (en) | Non-vesicular cationic lipid formulations | |
| Shi et al. | An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety | |
| CH684308A5 (de) | Liposomen enthaltend ein Allylamin. | |
| DE60025494T2 (de) | Epothilon zusammensetzungen | |
| Qin et al. | Nanotechnology-based drug delivery systems for treating acute kidney injury | |
| CN106913882B (zh) | 一种聚乙二醇-藤黄酸脂质体和制备方法及其在治疗恶性肿瘤中的应用 | |
| JP2023526707A (ja) | カバジタキセル弱塩基性誘導体およびその製剤 | |
| MX2010005862A (es) | Composiciones intravesicales con valrubicina para el tratamiento del cancer de vejiga. | |
| CN108883068A (zh) | 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法 | |
| CN1875022B (zh) | 生育酚修饰的治疗性药物化合物 | |
| JP2025026896A (ja) | リポソームドキソルビシン製剤、リポソームドキソルビシン製剤の製造方法、および薬剤としてのリポソームドキソルビシン製剤の使用 | |
| CN1700906A (zh) | 稳定的无菌过滤性脂质体包封的紫杉烷和其他抗肿瘤药物 | |
| KR101916941B1 (ko) | 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법 | |
| CN119212687A (zh) | 脂质纳米颗粒组合物及其使用方法 | |
| KR20250111222A (ko) | 신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자 |